Ophthalmic composition
An ophthalmic composition with azulene sulfonic acid and cyanocobalamin targets extraocular muscles to treat and prevent fatigue, addressing the inadequacies of existing compositions by delivering active ingredients directly to the muscles, thereby reducing inflammation and alleviating symptoms.
JP2026061540APending Publication Date: 2026-04-09ROHTO PHARM CO LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024170680
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2026-04-09
AI Technical Summary
Technical Problem
Existing ophthalmic compositions fail to directly target and treat or prevent fatigue of the extraocular muscles, which are prone to strain due to prolonged use of digital devices.
Method used
An ophthalmic composition containing azulene sulfonic acid, cyanocobalamin, or their salts, which can directly reach and act on the extraocular muscles to alleviate fatigue.
Benefits of technology
The composition effectively treats and prevents extraocular muscle fatigue by delivering active ingredients to the muscles, reducing inflammation and alleviating symptoms such as eye strain.
✦ Generated by Eureka AI based on patent content.
Abstract
To provide an ophthalmic composition directly reaching an external ocular muscle to treat or prevent its fatigue.SOLUTION: An ophthalmic composition comprising one or more compounds selected from the group consisting of azulene sulfonic acid, cyanocobalamin, and salts thereof, wherein the compound reaches an extraocular muscle. The ophthalmic composition contains one or more kinds of compounds selected from the group consisting of azulene sulfonic acid, cyanocobalamin and salts thereof and is used for the treatment and / or prevention of fatigue of an external ocular muscle.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art